Theravance Biopharma (TBPH) Restructuring Costs (2021 - 2026)

Theravance Biopharma (TBPH) has reported Restructuring Costs for 4 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Restructuring Costs changed N/A year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $3.8 million (changed N/A YoY), while the FY2023 annual figure was $2.7 million, down 78.57% from the prior year.
• Restructuring Costs advanced to $2.6 million in Q1 2026 per TBPH's latest filing, from $1.2 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $33.0 million in Q3 2022 and bottomed at -$38000.0 in Q4 2022.
• Historically, Restructuring Costs has averaged $11.9 million across 3 years, with a median of $2.6 million in 2026.
• On a YoY basis, Restructuring Costs climbed as much as 114.29% in 2022 and fell as far as 100.21% in 2022.
• Theravance Biopharma's Restructuring Costs stood at -$38000.0 in 2022, then surged by 3176.32% to $1.2 million in 2023, then jumped by 122.84% to $2.6 million in 2026.
• Business Quant data shows TBPH's Restructuring Costs at $2.6 million in Q1 2026, $1.2 million in Q2 2023, and $1.6 million in Q1 2023.